Login

Ye Tian

ORCID: 0009-0007-6084-8993
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5076916291
Research Areas
  • Galectins and Cancer Biology
  • Glycosylation and Glycoproteins Research
  • Immune Cell Function and Interaction
  • Phagocytosis and Immune Regulation
  • CAR-T cell therapy research

Shandong University
 2023-2024

 Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy
OPENALEX - Publications 
Rong Xiao Ye Tian Jiwei Zhang Na Li Mei Qi and 17 more Ling Liu Jianping Wang Zhenyu Li Jie Zhang Fabao Zhao Tixiao Wang Siyu Tan Chunyang Li Zhuanchang Wu Mingyan Yu Xuemei Jiang Peng Zhan Lifen Gao Bo Han Xinyong Liu Xiaohong Liang Chunhong Ma

10.1016/j.jhep.2024.01.028 article EN Journal of Hepatology 2024-02-07
 Identification of a small-molecule Tim-3 inhibitor to potentiate T cell–mediated antitumor immunotherapy in preclinical mouse models
OPENALEX - Publications 
Shuaiya Ma Ye Tian Jiali Peng Chaojia Chen Xueqi Peng and 22 more Fabao Zhao Zhenyu Li Mengzhen Li Fangcheng Zhao Xichun Sheng Runzhe Zong Yiquan Li Jiwei Zhang Mingyan Yu Qingfen Zhu Xiaoyu Tian Yuyang Li Markus Neckenig Huiqing Liu Peng Zhan Xuetian Yue Zhuanchang Wu Lifen Gao Xiaohong Liang Xinyong Liu Chunyang Li Chunhong Ma

T cell immunoglobulin and mucin-containing molecule 3 (Tim-3), expressed in dysfunctional exhausted cells, has been widely acknowledged as a promising immune checkpoint target for tumor immunotherapy. Here, using strategy combining virtual functional screening, we identified compound named ML-T7 that targets the FG-CC′ cleft of Tim-3, highly conserved binding site phosphatidylserine (PtdSer) carcinoembryonic antigen–related adhesion 1 (CEACAM1). enhanced survival antitumor activity primary...

10.1126/scitranslmed.adg6752 article EN Science Translational Medicine 2023-11-15
Coming Soon ...